Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal

Diabetes and Metabolism

Volumn 40, Issue 3, 2014, Pages 176-185

  Scheen, A J ^a   Charbonnel, B ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

Cardiovascular disease; Evidence based medicine; Microangiopathy; Outcome; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALOGLIPTIN; ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN GLARGINE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ACUTE CORONARY SYNDROME; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; WEIGHT GAIN; BLOOD; CHEMICALLY INDUCED; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG EFFECTS; HYPOGLYCEMIA; METABOLISM; MICROCIRCULATION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BLOOD GLUCOSE; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MICROCIRCULATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WEIGHT GAIN;

EID: 84902551303     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2014.03.004     Document Type: Note

References (84)

1. Retnakaran R., Zinman B. Type 1 diabetes, hyperglycaemia, and the heart. Lancet 2008, 371:1790-1799.
2. Paneni F., Beckman J.A., Creager M.A., Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 2013, 34:2436-2443.
3. Ryden L., Grant P.J., Anker S.D., Berne C., Cosentino F., Danchin N., et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013, 34:3035-3087.
4. Williams R., Van Gaal L., Lucioni C. Assessing the impact of complications on the costs of type II diabetes. Diabetologia 2002, 45:S13-S17.
5. Pirart J., Diabète et complications dégénératives. Présentation d'une étude prospective portant sur 4400 cas observés entre 1947 et 1973 (1ère, 2ème et 3ème parties). Diabet Metab 1977, 3:97-107. [73-82,245-56].
6. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
7. Ray K.K., Seshasai S.R., Wijesuriya S., Sivakumaran R., Nethercott S., Preiss D., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373:1765-1772.
8. Group UKPD.S. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
9. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
10. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
11. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
12. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
13. Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369:1317-1326.
14. White W.B., Cannon C.P., Heller S.R., Nissen S.E., Bergenstal R.M., Bakris G.L., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013, 369:1327-1335.
15. Boussageon R., Gueyffier F., Cornu C. Effects of pharmacological treatments on micro and macrovascular complications of type 2 diabetes: what is the level of evidence?. Diabetes Metab 2014, [in press]. 10.1016/j.diabet.2013.12.010.
16. Seshasai S.R., Kaptoge S., Thompson A., Di Angelantonio E., Gao P., Sarwar N., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364:829-841.
17. Sarwar N., Gao P., Seshasai S.R., Gobin R., Kaptoge S., Di Angelantonio E., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222.
18. Qiao Q., Tuomilehto J., Borch-Johnsen K. Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 2003, 46(Suppl.1):M17-M21.
19. Sarwar N., Aspelund T., Eiriksdottir G., Gobin R., Seshasai S.R., Forouhi N.G., et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Medicine 2010, 7:e1000278.
20. Beckman J.A., Paneni F., Cosentino F., Creager M.A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J 2013, 34:2444-2452.
21. Monnier L., Hanefeld M., Schnell O., Colette C., Owens D. Insulin and atherosclerosis: how are they related?. Diabetes Metab 2013, 39:111-117.
22. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
23. Lachin J.M., Orchard T.J., Nathan D.M. Update on cardiovascular outcomes at 30years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014, 37:39-43.
24. Purnell J.Q., Hokanson J.E., Marcovina S.M., Steffes M.W., Cleary P.A., Brunzell J.D. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the (DCCT) Diabetes Control and Complications Trial. JAMA 1998, 280:140-146.
25. Purnell J.Q., Zinman B., Brunzell J.D. The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study. Circulation 2013, 127:180-187.
26. Mazzone T., Chait A., Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008, 371:1800-1809.
27. Gerstein H.C., Bosch J., Dagenais G.R., Diaz R., Jung H., Maggioni A.P., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012, 367:319-328.
28. Group UKPDS Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34),UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:854-865.
29. Chaitman B.R., Hardison R.M., Adler D., Gebhart S., Grogan M., Ocampo S., et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009, 120:2529-2540.
30. Zoungas S., Patel A., Chalmers J., de Galan B.E., Li Q., Billot L., et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010, 363:1410-1418.
31. Bonds D.E., Miller M.E., Bergenstal R.M., Buse J.B., Byington R.P., Cutler J.A., et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010, 340:b4909.
32. Seaquist E.R., Miller M.E., Bonds D.E., Feinglos M., Goff D.C., Peterson K., et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care 2012, 35:409-414.
33. Mellbin L.G., Ryden L., Riddle M.C., Probstfield J., Rosenstock J., Diaz R., et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 2013, 34:3137-3144.
34. Hanefeld M., Duetting E., Bramlage P. Cardiac implications of hypoglycaemia in patients with diabetes-a systematic review. Cardiovasc Diabetol 2013, 12:135.
35. Scheen A.J., Van Gaal L.F. Combatting the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2014, 2. doi:10.1016/S2213-8587(14)70004-X.
36. Tobias D.K., Pan A., Jackson C.L., O'Reilly E.J., Ding E.L., Willett W.C., et al. Body mass index and mortality among adults with incident type 2 diabetes. N Engl J Med 2014, 370:233-244.
37. Fonseca V., McDuffie R., Calles J., Cohen R.M., Feeney P., Feinglos M., et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care 2013, 36:2162-2168.
38. Bodegard J., Sundstrom J., Svennblad B., Ostgren C.J., Nilsson P.M., Johansson G. Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: a cohort study of 8486 primary care patients. Diabetes Metab 2013, 39:306-313.
39. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004, 27:256-263.
40. Erdmann E., Charbonnel B., Wilcox R.G., Skene A.M., Massi-Benedetti M., Yates J., et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007, 30:2773-2778.
41. Erdmann E., Charbonnel B., Wilcox R. Thiazolidinediones and cardiovascular risk-a question of balance. Curr Cardiol Rev 2009, 5:155-165.
42. Scheen A.J. Outcomes and lessons from the PROactive study. Diabetes Res Clin Pract 2012, 98:175-186.
43. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
44. Home P.D., Pocock S.J., Beck-Nielsen H., Curtis P.S., Gomis R., Hanefeld M., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135.
45. Bach R.G., Brooks M.M., Lombardero M., Genuth S., Donner T.W., Garber A., et al. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 2013, 128:785-794.
46. The Diabetes Control Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
47. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
48. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003, 326:1419.
49. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
50. Strandberg T.E., Pyorala K., Cook T.J., Wilhelmsen L., Faergeman O., Thorgeirsson G., et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004, 364:771-777.
51. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
52. Sjostrom L., Peltonen M., Jacobson P., Sjostrom C.D., Karason K., Wedel H., et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012, 307:56-65.
53. Green J.B., Bethel M.A., Paul S.K., Ring A., Kaufman K.D., Shapiro D.R., et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J 2013, 166:e7983-e7989.
54. Zannad F., Stough W.G., Pocock S.J., Sleight P., Cushman W.C., Cleland J.G., et al. Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?. Eur Heart J 2012, 33:1049-1057.
55. Food Drug Administration Guidance for industry. Diabetes mellitus-Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes 2008, http://www.fdagov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627pdf [Accessed March 17, 2014].
56. Goldfine A.B. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008, 359:1092-1095.
57. Fullerton B., Jeitler K., Seitz M., Horvath K., Berghold A., Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014, 2:CD009122.
58. Adler A.I., Stevens R.J., Manley S.E., Bilous R.W., Cull C.A., Holman R.R. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225-232.
59. Yau J.W., Rogers S.L., Kawasaki R., Lamoureux E.L., Kowalski J.W., Bek T., et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012, 35:556-564.
60. National Kidney Foundation KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis 2012, 60:850-886.
61. Assogba F.G., Couchoud C., Hannedouche T., Villar E., Frimat L., Fagot-Campagna A., et al. Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007-2011. Diabetologia 2014, 57:718-728.
62. Hemmingsen B., Lund S.S., Gluud C., Vaag A., Almdal T.P., Hemmingsen C., et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2013, 11:CD008143.
63. Coca S.G., Ismail-Beigi F., Haq N., Krumholz H.M., Parikh C.R. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 2012, 172:761-769.
64. de Zeeuw D., Remuzzi G., Parving H.H., Keane W.F., Zhang Z., Shahinfar S., et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004, 65:2309-2320.
65. Ismail-Beigi F., Craven T., Banerji M.A., Basile J., Calles J., Cohen R.M., et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010, 376:419-430.
66. Perkovic V., Heerspink H.L., Chalmers J., Woodward M., Jun M., Li Q., et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013, 83:517-523.
67. Andresdottir G., Jensen M.L., Carstensen B., Parving H.H., Rossing K., Hansen T.W., et al. Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors. Diabetes Care 2014, [Epub ahead of print].
68. Mandal A.K., Hiebert L.M. Renal protection in diabetes: is it affected by glucose control or inhibition of the renin-angiotensin pathway?. Clin Nephrol 2008, 69:169-178.
69. Home P. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes. Diabetes Technol Ther 2012, 14(Suppl 1):S33-S42.
70. Seaquist E.R., Anderson J., Childs B., Cryer P., Dagogo-Jack S., Fish L., et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013, 36:1384-1395.
71. Wing R.R., Bolin P., Brancati F.L., Bray G.A., Clark J.M., Coday M., et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013, 369:145-154.
72. Turnbull F.M., Abraira C., Anderson R.J., Byington R.P., Chalmers J.P., Duckworth W.C., et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009, 52:2288-2298.
73. Boussageon R., Bejan-Angoulvant T., Saadatian-Elahi M., Lafont S., Bergeonneau C., Kassai B., et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011, 343:d4169.
74. Hemmingsen B., Lund S.S., Gluud C., Vaag A., Almdal T., Hemmingsen C., et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011, 343:d6898.
75. Smith G.C., Pell J.P. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ 2003, 327:1459-1461.
76. Potts M., Prata N., Walsh J., Grossman A. Parachute approach to evidence based medicine. BMJ 2006, 333:701-703.
77. Gregg E.W., Gu Q., Cheng Y.J., Narayan K.M., Cowie C.C. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 2007, 147:149-155.
78. Gregg E.W., Cheng Y.J., Saydah S., Cowie C., Garfield S., Geiss L., et al. Trends in death rates among US adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey. Diabetes Care 2012, 35:1252-1257.
79. Gulliford M.C., Charlton J. Is relative mortality of type 2 diabetes mellitus decreasing?. Am J Epidemiol 2009, 169:455-461.
80. Akalin S., Berntorp K., Ceriello A., Das A.K., Kilpatrick E.S., Koblik T., et al. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. Int J Clin Pract 2009, 63:1421-1425.
81. Working Group on the summit on combination therapy for CVD Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. Eur Heart J 2014, 35:353-364.
82. Bell D.S., Patil H.R., O'Keefe J.H. Divergent effects of various diabetes drugs on cardiovascular prognosis. Rev Cardiovasc Med 2013, 14:e107-e122.
83. Schwartz S.S., Kohl B.A. Glycemic control and weight reduction without causing hypoglycemia: the case for continued safe aggressive care of patients with type 2 diabetes mellitus and avoidance of therapeutic inertia. Mayo Clin Proc 2010, 85:S15-S26.
84. Giorgino F., Leonardini A., Laviola L. Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. Ann N Y Acad Sci 2013, 1281:36-50.